1. National Kidney and Urologic Disease Information Clearinghouse. Adult Kidney Stones. http://kidney.niddk.nih.gov/Kudiseases/pubs/stonesadults/
2. Дасаева Л.А., Шилов Е.М., Шатохина С.Н. Современные представления об этиологии и патогенезе формирования мочевых камней. Нефрология и диализ. 2003; 5 (2). http://www.nephro.ru/magazine/article.php?id=17395
3. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911–30.
4. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl 
J Med 2010; 363 (10): 954–63.
5. Balzer K, Bremer M, Schramm S et al. Falls prevention for the elderly. GMS Health Technol Assess 2012; 8 (1).
6. Annweiler C, Fantino B, Gautier J et al. Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre-post study. J Am Geriatr Soc 2012; 60 (4): 793–5.
7. Holick MF. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002; 9: 87–98.
8. Wasserman RH, Fullmer CS. Vitamin D and intestinal calcium transport: facts, speculations and hypotheses. J Nutr 1995; 125: 1971S–1979S.
9. Nemere I, Leathers V, Norman AW. 1,25-Dihydroxyvitamin D3-mediated intestinal calcium transport. Biochemical identification of lysosomes containing calcium and calcium-binding protein (calbindin-D28K). 
J Biol Chem 1986; 261: 16106–14.
10. Winaver J, Sylk DB, Robertson JS et al. Micropuncture study of the acute renal tubular transport effects of 25-hydroxyvitamin D3 in the dog. Miner Electrolyte Metab 1980; 4: 178–88.
11. Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev 2005; 85: 373–422.
12. Hawa NS, O'Riordan JL, Farrow SM. Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene. Biochem Biophys Res Commun 1996; 228: 352–7.
13. Мирная С.С., Пигарова Е.А., Беляева А.В. и др. Роль кальций-чувствительного рецептора в поддержании системы кальциевого гомеостаза. Остеопороз и остеопатии. 2010; 3: 32–6.
14. Kurose H, Yamaoka K, Okada S et al. 1,25-Dihydroxyvitamin D3 
[1,25-(OH)2D3] increases insulin-like growth factor I (IGF-I) receptors in clonal osteoblastic cells. Study on interaction of IGF-I and 1,25-(OH)2D3. Endocrinology 1990; 126: 2088–94.
15. Sato T, Ono T, Tuan RS. 1,25-Dihydroxy vitamin D3 stimulation of TGF-beta expression in chick embryonic calvarial bone. Differentiation 1993; 52: 139–50.
16. Wang DS, Yamazaki K, Nohtomi K et al. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res 1996; 11: 472–9.
17. Lacey DL, Grosso LE, Moser SA et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 1993; 91: 1731–42.
18. Alpern RJ, Hebert SC. Seldin and Giebisch's The Kidney (4th edition). Acad Press 2007; p. 1851–90.
19. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Nat Acad Press 2010.
20. Cranney C, Horsely T, O'Donnell S et al. Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 prepared by the University of Ottawa Evidence-based Practice Center under Contract No. 290-02.0021. AHRQ Publication No. 07-E013. Rockville, MD: Agency for Healthcare Research and Quality 2007.
21. Norman AW, Henry HH. Vitamin D. In: Bowman BA, Russell RM, eds. Present Knowledge in Nutrition, 9th ed. Washington DC: ILSI Press, 2006.
22. Плещева А.В., Пигарова Е.А., Дзеранова Л.К. Распространенность дефицита витамина Д и его влияние на физические функции у пациенток в перименопаузе с синдромом хронической усталости (СХУ). Тезисы Всерос. науч.-практ. конф. c междунар. уч. «Алмазовские чтения 2011», посвященной 80-летию со дня рождения академика РАМН В.А.Алмазова. СПб., 2011.
23. El-Hajj Fuleihan G, Nabulsi M, Tamim H et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006; 91: 405–12.
24. Heaney RP, Davies KM, Chen TC et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204–10.
25. Марова Е.И., Родионова С.С., Рожинская Л.Я., Шварц Г.Я. Альфакальцидол (Альфа-Д3) в профилактике и лечении остеопороза. Метод. рекомендации. М., 1998.
26. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17 (Suppl. 10): 10–9.
27. Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. 
J Urol 1989; 142: 1516–21. Sakhaee et al. Kidney Stones 1856. J Clin Endocrinol Metab 2012; 97 (6): 1847–60.
28. Evan AP, Lingeman JE, Coe FL et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 2005; 67: 576–91.
29. Дзеранов Н.К., Лопаткин Н.А. Мочекаменная болезнь. Клин. рекомендации. М.: Оврелей, 2007; с. 296.
30. Looker AC, Pfeiffer CM, Lacher DA et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2003–2004. Am J Clin Nutr 2008; 88: 1519–27.
31. MacLaughlin J, Holick MF. Aging decreases the capacity of the human skin to produce vitamin D3. J Clin Invest 1985; 76: 1536–8.
32. Khashayar Sakhaee, Naim M, Maalouf, Bridget Sinnott. Kidney Stones 2012: Pathogenesis, Diagnosis and Management. J Clin Endocrinol Metab 2012; 97 (6): 1847–60.
33. Henneman PH, Benedict PH, Forbes AP, Dudley HR. Idiopathic hypercaicuria. N Engl J Med 1958; 259: 802–7.
34. Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008; 28: 120–32.
35. Pak CY, Oata M, Lawrence EC, Snyder W. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. J Clin Invest 1974; 54: 387–400.
36. Broadus AE, Insogna KL, Lang R et al. A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. J Clin Endocrinol Metab 1984; 58: 161–9.
37. Insogna KL, Broadus AE, Dreyer BE et al. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. 
J Clin Endocrinol Metab 1985; 61: 490–5.
38. Pak CY, East DA, Sanzenbacher LJ et al. Gastrointestinal calcium absorption in nephrolithiasis. J Clin Endocrinol Metab 1972; 35: 261–70.
39. Kaplan RA, Haussler MR, Deftos LJ et al. The role of 1,25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59: 756–60.
40. Birge SJ, Peck WA, Berman M, Whedon GD. Study of calcium absorption in man: a kinetic analysis and physiologic model. J Clin Invest 1969; 48: 1705–13.
41. Maierhofer WJ, Gray RW, Cheung HS, Lemann Jr J. Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int 1983; 24: 555–60.
42. Breslau NA, Preminger GM, Adams BV et al. Use of ketoconazole to probe the pathogenetic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. J Clin Endocrinol Metab 1992; 75: 1446–52.
43. Barilla DE, Zerwekh J, Pak CY. A critical evaluation of the role of phosphate in the pathogenesis of absorptive hypercalciuria. Miner Electrolyte Metab 1979; 2: 302–9.
44. Zerwekh JE, Pak CY, Kaplan RA et al. Pathogenetic role of 1,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab 1980; 51: 381–6.
45. Bushinsky DA, Grynpas MD, Nilsson EL et al. Stone formation in genetic hypercalciuric rats. Kidney Int 1995; 48: 1705–13.
46. Bushinsky DA, Asplin JR, Grynpas MD et al. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2002; 61: 975–87.
47. Li XQ, Tembe V, Horwitz GM et al. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest 1993; 391: 661–7.
48. Tsuruoka S, Bushinsky DA, Schwartz GJ. Defective renalcalcium reabsorption in genetic hypercalciuric rats. Kidney Int 1997; 51: 1540–7.
49. Karnauskas AJ, van Leeuwen JP, van den Bemd GJ et al. Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. J Bone Miner Res 2005; 20: 447–54.
50. Favus MJ, Karnauskas AJ, Parks JH, Coe FL. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89: 4937–40.
51. Pak CY. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991; 18: 624–37.
52. Pak CY, Nicar MJ, Peterson R et al. Alack of unique pathophysiologic background for nephrolithiasis of primary hyperparathyroidism. J Clin Endocrinol Metab 1981; 53: 536–42.
53. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011; 96: 2377–85.
54. Patron P, Gardin JP, Paillard M. Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism. Kidney Int 1987; 31: 1174–80.
55. Odvina CV, Sakhaee K, Heller HJ et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol Res 2007; 35: 123–8.
56. Stamatelou KK, Francis ME, Jones CA et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63 (5): 1817–23.
57. Netelenbos JC, Jongen MJ, van der Vijgh WJ et al. Vitamin D status in urinary calcium stone formation. Arch Intern Med 1985; 145 (4): 681–4.
58. Khashayar Sakhaee, Naim M, Maalouf et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011; 79 (4): 393–403. doi:10.1038/ki.2010.473
59. Penniston KL, Jones AN, Nakada SY, Hansen KE. Vitamin D repletion does not alter urinary calcium excretion in healthy postmenopausal women. BJU Int 2009; 104 (10): 1512–6.
60. Elkoushy MA, Sabbagh R, Unikowsky B, Andonian S. Prevalence and metabolic abnormalities of vitamin D-inadequate patients presenting with urolithiasis to a tertiary stone clinic. Urology 2012; 79 (4): 781–5.
61. Taylor WH. Renal calculi and self-medication with multivitamin preparations containing vitamin D. Clin Sci 1972; 42: 515–22.
62. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–83.
63. Пигарова E.A., Мирная С.С., Беляева А.В и др. Анализ биохимических предикторов нефролитиаза у пациентов с первичным гиперпаратиреозом. Мат. Всерос. науч.-практ. конф. c междунар. уч. «Алмазовские чтения 2011», посвященной 80-летию со дня рождения академика РАМН В.А.Алмазова. СПб., 2011.

С.Ю.Калинченко1, Е.А.Пигарова2, Д.А.Гусакова3, А.В.Плещева2

1. ФПКМР ГОУ ВПО Российский университет дружбы народов Минздрава РФ, Москва;
2. ФГБУ Эндокринологический научный центр Минздрава РФ, Москва;
3. ФГБУ НИИ урологии Минздрава РФ, Москва